Literature DB >> 11834374

CFTR mutations and host susceptibility to Pseudomonas aeruginosa lung infection.

Gerald B Pier1.   

Abstract

The susceptibility of cystic fibrosis patients to bacterial pathogens is associated with deficient airway antimicrobial peptide activity, and airway-surface-liquid dehydration with decreased transport velocity and hypersecretion of mucus. Susceptibility to Pseudomonas aeruginosa infection has been linked to the role of the cystic fibrosis transmembrane conductance regulator protein as a receptor for P. aeruginosa. Binding of P. aeruginosa coordinates lung clearance as part of innate immunity. The function of CFTR in innate immunity to P. aeruginosa infection is multifactorial, with one key component being a specific ligand-receptor interaction between the protein and the microbe.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834374     DOI: 10.1016/s1369-5274(02)00290-4

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  26 in total

1.  Cystic fibrosis presenting with corneal perforation and crystalline lens extrusion.

Authors:  Danielle S Hall; Saurabh Goyal
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

2.  Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.

Authors:  Christian Mueller; Sofia A Braag; Allison Keeler; Craig Hodges; Mitchell Drumm; Terence R Flotte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-19       Impact factor: 6.914

3.  Induced conformational changes in the activation of the Pseudomonas aeruginosa type III toxin, ExoU.

Authors:  Marc A Benson; Steven M Komas; Katherine M Schmalzer; Monika S Casey; Dara W Frank; Jimmy B Feix
Journal:  Biophys J       Date:  2011-03-02       Impact factor: 4.033

4.  The structure of the BfrB-Bfd complex reveals protein-protein interactions enabling iron release from bacterioferritin.

Authors:  Huili Yao; Yan Wang; Scott Lovell; Ritesh Kumar; Anatoly M Ruvinsky; Kevin P Battaile; Ilya A Vakser; Mario Rivera
Journal:  J Am Chem Soc       Date:  2012-08-01       Impact factor: 15.419

5.  Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency.

Authors:  R Sebro; H Levy; K Schneck; D Dimmock; B A Raby; C L Cannon; U Broeckel; N J Risch
Journal:  Clin Genet       Date:  2011-11-29       Impact factor: 4.438

6.  Surface association and the MreB cytoskeleton regulate pilus production, localization and function in Pseudomonas aeruginosa.

Authors:  Kimberly N Cowles; Zemer Gitai
Journal:  Mol Microbiol       Date:  2010-04-12       Impact factor: 3.501

7.  alpha5beta1 integrins and fibronectin are involved in adherence of the Pseudomonas aeruginosa ER97314 clinical strain to A549 cells.

Authors:  H Gagnière; P Di Martino
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

8.  Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients.

Authors:  Matthew C Wolfgang; Jeevan Jyot; Andrew L Goodman; Reuben Ramphal; Stephen Lory
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

9.  Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection.

Authors:  Fadie T Coleman; Simone Mueschenborn; Gloria Meluleni; Christopher Ray; Vincent J Carey; Sara O Vargas; Carolyn L Cannon; Frederick M Ausubel; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

10.  Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor.

Authors:  Nina Reiniger; Martin M Lee; Fadie T Coleman; Christopher Ray; David E Golan; Gerald B Pier
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.